Abstract: The objective of the study was to illustrate the utility of positron emission tomography (PET) imaging using [
C]PIB retention and CSF levels of Ab42 in both patients resembled those of controls suggesting the presence of nonamyloid pathology. Genetic testing confirmed the absence of mutations in the presenilin 1 gene in 1 patient; subsequent testing revealed the R406W tau mutation in both individuals leading to a diagnosis of frontotemporal dementia [ 18 F]FDDNP retention broadly correlated with CSF levels of t-tau and p-tau. Despite both individuals harbouring the same mutation, [ 18 F]FDDNP retention and CSF t-tau and p-tau were elevated in 1 patient, but not in the other. T he prospect of disease modifying drugs for Alzheimer's disease (AD) means that distinguishing AD both from normal ageing and from different forms of dementia is becoming increasingly important. Potential in vivo biomarkers of AD pathology, including positron emission tomography (PET) with, among others, [ 11 2 Reduction of amyloid-b1 to 42 (Ab42) and increase in levels of total tau (t-tau) and tau phosphorylated at threonine 181 (p-tau) in CSF have been shown to be of diagnostic value in AD. 3 Patients with confirmed genetic mutations leading to autosomal dominant inherited dementia syndromes provide a unique opportunity to examine the specificity of such biomarkers in vivo. In this report, we describe 2 siblings with progressive cognitive deterioration clinically resembling AD in whom biomarkers suggested the absence of underlying amyloid pathology, a suspicion subsequently confirmed by the identification of the R406W tau mutation leading to a diagnosis of frontotemporal dementia (FTD). 4 
METHODS

Patients
Two siblings with an AD clinical phenotype were included in this imaging study. Nine patients fulfilling criteria for probable sporadic AD and 6 healthy controls were used to provide normative imaging data. 5 All participants received a standard dementia screening including medical history, physical and neurologic examinations, screening laboratory tests, brain MRI, and neuropsychologic testing. Clinical diagnosis was established according to standard consensus criteria in a multidisciplinary meeting. All AD patients met NINCDS-ADRDA 6 criteria for probable AD. Written informed consent was obtained from all participants. The study was approved by the Medical Ethics Review Committee of the VU University Medical Centre, Amsterdam.
CSF Analysis
CSF Ab42, t-tau and p-tau were measured with Innotest (Innogenetics, Ghent, Belgium) sandwich ELISAs, as described earlier. 3 
Positron Emission Tomography
Genetic Testing
After appropriate counseling, testing for specific mutations in presenilin 1, the gene most frequently associated with familial AD, was conducted in patient 1; screening for mutations in the tau gene was subsequently carried out in both patients. Exon 13 of MAPT, including intron/exon boundaries was amplified from genomic DNA according to the subsequent conditions 7 : reaction volume was 15 mL with a final concentration of 10 mM Tris-HCL (pH8.3), 50 mM KCl, 1,5 mM MgCl2, and 250 mM dNTPS; Platinum Taq polymerase at 0,35 units/15mL; primers at 10 pmol/mL and 15 ng template genomic DNA. PCR reactions were sequenced in both strands and run on an automated DNA sequencer (ABI 3730).
RESULTS
Patient 1
The patient was a 61-year-old male who complained of progressive episodic memory impairment since 7 years. There was a positive family history of dementia: his grandfather, father, 2 uncles, and 1 aunt on his father's side had developed dementia before the age of 60. The Mini Mental State Examination (MMSE) score was 29/30. Magnetic resonance imaging (MRI) of the brain revealed pronounced isolated bilateral, symmetrical, medial, temporal lobe atrophy, especially in the anterior part (Fig. 1A) . Neuropsychologic testing revealed problems with registration and retention of verbal information and poor face recognitionwith no impairment on executive functions. A clinical diagnosis of amnestic MCI, 8 probably owing to incipient familial AD, was made.
Patient 2
Concurrently, the patient's sister, a 59-year-old woman, also sought medical attention for evaluation of cognitive decline. She presented with similar, but more severe, complaints than her brother leading to interference of activities of daily living. The MMSE score was 26/30. MRI of the brain revealed a similar, though more profound, pattern of selective hippocampal atrophy (Fig. 1B) . Neuropsychological testing revealed problems with registration and retention of verbal information with no impairment on executive functions. A clinical diagnosis of AD, probably owing to familial AD, was made.
CSF
A lumbar puncture was carried out at the initial visit for both patients. CSF Ab42 levels were within normal limits (patient 1:933 pg/mL, normal range 3 (NR)>495 pg/mL; patient 2:1026 pg/mL). T-tau and p-tau levels were normal in patient 1 (340 pg/mL, NR<356 pg/mL and 51 pg/mL, NR <54 pg/mL, respectively). Both were elevated in patient 2 (t-tau: 442 pg/mL; p-tau 63 pg/mL). 
Control
Siblings AD 18 F]FDDNP data of 9 AD patients (age 62 ± 4 y, MMSE 24 ± 3) and 6 healthy controls (age 61 ± 3 y, MMSE 30 ± 1). 5 Global and regional [ 11 C]PIB uptake of both patients was similar to that of controls. Patient 1 displayed low [
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18 F]FDDNP uptake, both compared with controls and AD; patient 2 had an intermediate level of binding lying within the range of both the AD patients and the controls (Fig. 3) . Patient 1 had higher [ 18 F]FDDNP binding than seen in the AD group in the medial temporal lobe, whereas patient 2 displayed increased binding similar to mean binding in AD in frontal and parietal lobes and posterior cingulate (Table 1) .
Genetic Testing
No specific mutations in the presenilin 1 gene were found in patient 1; subsequent screening revealed the R406W tau mutation in both patients.
DISCUSSION
By studying the patients with rare autosomal dominantly inherited dementias, in whom a definitive diagnosis can be made in vivo, the specificity of biomarkers can be tested. This study illustrates the power of CSF and [
11 C]PIB PET in refuting the presence of amyloid pathology in patients fulfilling the clinical criteria of AD. Moreover, it reveals the potential value of the combination of biomarkers for the differential diagnosis of (sporadic) FTD from AD. Elevated levels of the CSF t-tau and p-tau values together with normal [
11 C]PIB imaging and CSF measures of Ab42 have proved to be highly suggestive of FTD.
In the 2 patients described, the clinical phenotype of slowly progressive episodic memory loss with profound hippocampal atrophy is in line with earlier reports on patients with FTD owing to the R406W tau mutation. 9, 10 Normal [
11 C]PIB uptake and CSF Ab42 correspond with the neuropathology, typically associated with this mutation, that is neurofibrillary tangles in the absence of Ab plaques, [11] [12] [13] [14] although concomitant presence of numerous plaques has been reported in the 2 patients . 
